FDA Approves BUPRENORPHINE — Rhodes Pharmaceuticals LLC

Rhodes Pharmaceuticals LLC has received approval for its Abbreviated New Drug Application (ANDA) for Buprenorphine Hydrochloride sublingual tablets, positioning the company to capitalize on significant market demand for the opioid dependence treatment as patents for multiple competing products expire. This approval expands Rhodes’ portfolio within the generic narcotic sector and accelerates its ability to compete in a rapidly evolving market environment.